Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NantHealth, Inc. (NH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5763+0.0212 (+3.82%)
At close: 04:00PM EDT
0.5800 +0.00 (+0.64%)
After hours: 07:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5551
Open0.5200
Bid0.5600 x 800
Ask0.5800 x 1300
Day's Range0.5200 - 0.5899
52 Week Range0.4010 - 2.5100
Volume47,327
Avg. Volume121,719
Market Cap66.591M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.5100
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NantHealth, Inc.
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Motley Fool

    NantHealth, Inc. (NH) Q2 2022 Earnings Call Transcript

    Image source: The Motley Fool. NantHealth, Inc. (NASDAQ: NH)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the NantHealth 2022 second quarter financial results conference call.

  • Business Wire

    NantHealth Reports 2022 Second Quarter Financial Results

    MORRISVILLE, N.C., August 04, 2022--NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its second quarter ended June 30, 2022.

  • Business Wire

    NantHealth to Report 2022 Second-Quarter Financial Results and Host Conference Call on Thursday, August 4

    MORRISVILLE, N.C., August 01, 2022--NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 second quarter on Thursday, August 4, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company’s performance.

Advertisement
Advertisement